Medicus Pharma Rings Nasdaq Bell After Year of Pipeline Advances
Event summary
- Medicus Pharma (NASDAQ: MDCX) will ring the Nasdaq Opening Bell on January 22, 2026, marking its one-year anniversary as a listed company.
- The company's pipeline includes SkinJect for basal cell carcinoma ($2B market) and Teverelix for advanced prostate cancer ($6B market).
- SkinJect Phase 2 study (SKNJCT-003) enrollment completed with 90 patients; topline results expected Q1 2026.
- Teverelix Phase 2b studies approved by FDA for advanced prostate cancer (40 patients) and AURr (390 patients).
- Non-binding MoU with Helix Nanotechnologies for potential mRNA platform collaboration.
The big picture
Medicus Pharma's Nasdaq anniversary comes as it advances two high-potential therapies targeting multi-billion-dollar markets. The company's focus on disciplined execution and strategic partnerships reflects broader industry trends toward capital-efficient development and collaborative commercialization strategies. With SkinJect nearing critical data readouts and Teverelix in late-stage trials, Medicus is positioning itself for potential licensing deals or strategic exits.
What we're watching
- Clinical Readouts
- How SkinJect Phase 2 topline results will impact potential partnering opportunities.
- Regulatory Pathways
- Whether Medicus can secure an end-of-Phase 2 meeting with the FDA for SkinJect in H1 2026.
- Strategic Partnerships
- The pace at which Medicus advances non-binding agreements with HelixNano and Reliant AI into definitive deals.
Related topics